| Literature DB >> 9701024 |
Y Levy1, B Gilburd, J George, N Del Papa, R Mallone, M Damianovich, M Blank, A Radice, Y Renaudineau, P Youinou, A Wiik, F Malavasi, P L Meroni, Y Shoenfeld.
Abstract
The IgG fraction of human anti-endothelial cell antibodies (AECA) obtained from a patient with Wegener's granulomatosis was used as immunogen to raise AECA mAb in mice selected among those which developed vasculitis-like lesions after immunization. Three mAb (BGM, 3C8 and 7G2), selected by cyto-ELISA and flow cytometry analyses, featured a specific reactivity with human umbilical vein endothelial cells (HUVEC) and the mouse endothelial cell line H5V; on the contrary, HEp2 cells, the murine melanoma B16 cell line, the extracellular matrix as well as several other antigens tested were not recognized. BGM mAb, an IgG3 precipitating a 70 kDa structure from HUVEC, was able to induce endothelial cells to secrete amounts of IL-6 significantly higher than irrelevant controls or mAb binding different endothelial antigens (i.e. CD31, CD29, ICAM-1 and HLA class I). BGM mAb induced significant levels of antibody-dependent cell cytotoxicity (13 +/- 2.5 versus 0.6 +/- 0.03%). To the best of our knowledge, BGM is the first murine mAb specific for human endothelial cells generated by idiotypic manipulation; secondly, its biological properties further support the notion of a pathogenic role for AECA in autoimmune-mediated diseases.Entities:
Mesh:
Substances:
Year: 1998 PMID: 9701024 DOI: 10.1093/intimm/10.7.861
Source DB: PubMed Journal: Int Immunol ISSN: 0953-8178 Impact factor: 4.823